Bicycle Therapeutics PLC (BCYC)
21.38
-0.80
(-3.63%)
USD |
NASDAQ |
May 17, 16:00
21.38
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Cash from Investing (Quarterly): -0.012M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.012M |
| December 31, 2023 | -0.051M |
| September 30, 2023 | -0.502M |
| June 30, 2023 | -0.277M |
| March 31, 2023 | -2.099M |
| December 31, 2022 | -1.448M |
| September 30, 2022 | -2.984M |
| June 30, 2022 | -9.799M |
| March 31, 2022 | -4.756M |
| December 31, 2021 | -1.067M |
| September 30, 2021 | -0.169M |
| June 30, 2021 | -0.171M |
| March 31, 2021 | -0.623M |
| Date | Value |
|---|---|
| December 31, 2020 | -0.484M |
| September 30, 2020 | -0.095M |
| June 30, 2020 | -0.301M |
| March 31, 2020 | -0.32M |
| December 31, 2019 | -0.391M |
| September 30, 2019 | -0.283M |
| June 30, 2019 | -0.463M |
| March 31, 2019 | -0.418M |
| December 31, 2018 | -0.41M |
| September 30, 2018 | -0.126M |
| June 30, 2018 | -0.386M |
| March 31, 2018 | -0.264M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-9.799M
Minimum
Jun 2022
-0.012M
Maximum
Mar 2024
-1.315M
Average
-0.427M
Median
Cash from Investing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 0.0038M |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | -0.358M |
| Verona Pharma PLC | -0.016M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -70.87M |
| Cash from Financing (Quarterly) | 1.871M |
| Free Cash Flow | -85.93M |
| Free Cash Flow Per Share (Quarterly) | -1.665 |
| Free Cash Flow to Equity (Quarterly) | -70.98M |
| Free Cash Flow to Firm (Quarterly) | -70.88M |
| Free Cash Flow Yield | -10.39% |